|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009429,
umls-concept:C0030705,
umls-concept:C0032285,
umls-concept:C0036043,
umls-concept:C0087111,
umls-concept:C0205265,
umls-concept:C0439858,
umls-concept:C0536495,
umls-concept:C0556895,
umls-concept:C1555582,
umls-concept:C1705294
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2004-10-22
|
|
pubmed:abstractText |
To compare the efficacy of sequential i.v. to p.o. moxifloxacin with ceftriaxone +/- azithromycin +/- metronidazole for the treatment of patients with community acquired pneumonia (CAP), a multi-centered, prospective, randomized, open label study was performed. CAP patients were randomized to moxifloxacin (400 mg/d-at least one i.v. dose) or ceftriaxone (at least one dose of 2 g i.v. q.d. followed by cefuroxime 500 mg p.o. b.i.d.) +/- azithromycin, +/- metronidazole (cephalosporin/macrolide control: CMC). The primary endpoint was clinical response at test-of-cure (TOC) visit. Bacteriological response at TOC was the secondary endpoint. Clinical cure was found in 83.3% (90/108) of moxifloxacin patients and 79.6% (90/113) of control patients. Microbiological responses were 81.8% (18/22) for moxifloxacin and 60.7% (17/28) for CMC patients. Drug-related adverse events occurred in 18.0% of moxifloxacin and 16% of CMC patients. It is concluded that i.v. to p.o. moxifloxacin is as effective as CMC for treatment of CAP and is a reliable alternative antimicrobial therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0736-4679
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
395-405
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15498622-Adult,
pubmed-meshheading:15498622-Aged,
pubmed-meshheading:15498622-Aged, 80 and over,
pubmed-meshheading:15498622-Anti-Bacterial Agents,
pubmed-meshheading:15498622-Aza Compounds,
pubmed-meshheading:15498622-Azithromycin,
pubmed-meshheading:15498622-Ceftriaxone,
pubmed-meshheading:15498622-Community-Acquired Infections,
pubmed-meshheading:15498622-Constipation,
pubmed-meshheading:15498622-Drug Therapy, Combination,
pubmed-meshheading:15498622-Emergency Medical Services,
pubmed-meshheading:15498622-Female,
pubmed-meshheading:15498622-Humans,
pubmed-meshheading:15498622-Male,
pubmed-meshheading:15498622-Metronidazole,
pubmed-meshheading:15498622-Middle Aged,
pubmed-meshheading:15498622-Nausea,
pubmed-meshheading:15498622-Pneumonia, Bacterial,
pubmed-meshheading:15498622-Prospective Studies,
pubmed-meshheading:15498622-Quinolines,
pubmed-meshheading:15498622-Safety,
pubmed-meshheading:15498622-Time Factors,
pubmed-meshheading:15498622-Treatment Outcome
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy.
|
|
pubmed:affiliation |
Washington University, St. Louis, Missouri 63110, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
